Table 1.
Summary of characteristics of 191 patients.
| Characteristic | Value | Soft | Fibrous | Hard | p |
|---|---|---|---|---|---|
| Mean age±SD, years | 47.9±14 | 47.5±14 | 49.8±14 | 47.2±14 | 0.641 |
| Sex | 0.772 | ||||
| Male | 91 (47.6%) | 59 (53.2%) | 19 (47.5%) | 22 (55%) | |
| Female | 100 (52.4%) | 52 (46.8%) | 21 (52.5%) | 18 (45%) | |
| Size | 0.255 | ||||
| Micro ≤1 cm | 4 (2.1%) | 2 (1.8%) | 0 (0.0%) | 2 (5.0%) | |
| Large 1–4 cm | 163 (85.3%) | 91 (82.0%) | 37 (92.5%) | 35 (87.5%) | |
| Giant >4 cm | 24 (12.6%) | 18 (16.2%) | 3 (7.5%) | 3 (7.5%) | |
| Knosp grade | 0.369 | ||||
| 0 | 11 (5.8%) | 5 (4.5%) | 4 (10.0%) | 2 (5.0%) | |
| 1 | 38 (19.9%) | 22 (19.8%) | 9 (22.5%) | 7 (17.5%) | |
| 2 | 44 (23.0%) | 21 (18.9%) | 9 (22.5%) | 14 (35.0%) | |
| 3 | 33 (17.3%) | 18 (16.2%) | 8 (20.0%) | 7 (17.5%) | |
| 4 | 65 (34.0%) | 45 (40.5%) | 10 (25.0%) | 10 (25.0%) | |
| Preoperative hematological parameters | |||||
| ACTH 8am pg/mL | 37.96±32.23 | 36.90±34.78 | 38.39±27.56 | 40.70±29.51 | 0.858 |
| ACTH 4pm pg/mL | 22.03±22.13 | 20.95±17.43 | 26.13±30.25 | 20.63±24.31 | 0.497 |
| PRL mIU/L | 416.90 (204.60–830.00) | 385.80 (197.10–803.00) | 497.70 (296.35–967.65) | 328.30 (204.50–844.00) | 0.387 |
| GH ug/L | 92.37±1058 | 147.71±1378 | 7.41±17.09 | 18.35±52.12 | 0.721 |
| TSH mIU/L | 2.34±3.90 | 2.03±2.71 | 3.39±6.92 | 2.21±2.31 | 0.198 |
| FSH IU/L | 15.64±26.87 | 16.56±30.65 | 12.81±16.43 | 15.96±24.24 | 0.768 |
| LH IU/L | 5.26±7.66 | 5.52±8.94 | 4.76±5.72 | 5.01±5.1 | 0.857 |
| Main complain | |||||
| Excessive hormone secretion | 25 (13.2%) | 13 (11.8%) | 6 (15.0%) | 6 (15.0%) | |
| Insufficient hormone secretion | 26 (13.7%) | 15 (13.6%) | 4 (10.0%) | 7 (17.5%) | |
| Compression of surrounding structure | 118 (62.1%) | 75 (68.2%) | 22 (55.0%) | 21 (52.5%) | |
| Tumor stroke | 5 (2.6%) | 1 (0.9%) | 2 (5.0%) | 2 (5.0%) | |
| Absence of symptoms | 16 (8.4%) | 6 (5.5%) | 6 (15.0%) | 4 (10.0%) | |
| Hematological index after surgery (Day 1) | |||||
| ACTH 8 am pg/mL | 41.33±77.64 | 35.72±52.61 | 62.02±131.05 | 28.00±18.93 | 0.329 |
| ACTH 4 pm pg/mL | 59.86±101.11 | 75.71±114.78 | 55.38±77.99 | 68.09±57.28 | 0.739 |
| PRL mIU/L | 207.80 (91.90–524.80) | 191.15 (78.09–531.08) | 312.85 (187.65–570.50) | 181.40 (45.94–305.40) | 0.604 |
| GH ug/L | 5.95±10.89 | 5.74±11.26 | 6.54±12.08 | 5.96±8.08 | 0.962 |
| TSH mIU/L | 5.39±40.63 | 7.94±52.17 | 1.83±3.42 | 1.02±1.00 | 0.702 |
| FSH IU/L | 10.40±11.98 | 10.37±12.98 | 9.78±9.75 | 11.66±11.87 | 0.896 |
| LH IU/L | 4.84±6.32 | 4.37±6.15 | 4.60±5.79 | 7.50±7.87 | 0.263 |
| Immunohistochemical subtypes | 0.001* | ||||
| ACTH positive | 6 (3.1%) | 5 (4.5%) | 1 (2.5%) | 0 (0.0%) | |
| FSH positive | 30 (15.7%) | 8 (7.2%) | 14 (35.0%) | 8 (20.0%) | |
| GH positive | 4 (2.1%) | 3 (2.7%) | 0 (0.0%) | 1 (2.5%) | |
| LH positive | 1 (0.5%) | 1 (0.9%) | 0 (0.0%) | 0 (0.0%) | |
| PRL positive | 18 (9.4%) | 11 (9.9%) | 5 (12.5%) | 2 (5.0%) | |
| TSH positive | 1 (0.5%) | 0 (0.0%) | 0 (0.0%) | 1 (2.5%) | |
| Multiple items positive | 17 (8.9%) | 9 (8.1%) | 4 (10.0%) | 4 (10.0%) | |
| Negative | 110 (57.6%) | 71 (64.0%) | 15 (37.5%) | 24 (60.0%) | |
| Residual adenoma invading cavernous sinus | 0.912 | ||||
| No | 104 (61.5%) | 60 (60.6%) | 22 (61.1%) | 22 (64.7%) | |
| Yes | 65 (38.5%) | 39 (39.4%) | 14 (38.9%) | 12 (35.3%) | |
| Complication | 0.333 | ||||
| No | 174 (91.1%) | 103 (92.8%) | 34 (85.0%) | 37 (92.5%) | |
| Yes | 17 (8.9%) | 8 (7.2%) | 6 (15.0%) | 3 (7.5%) | |